Document
DailyMed Label: MYHIBBIN
Title
DailyMed Label: MYHIBBIN
Date
2024
Document type
DailyMed Prescription
Name
MYHIBBIN
Generic name
MYCOPHENOLATE MOFETIL
Manufacturer
Azurity Pharmaceuticals, Inc.
Product information
NDC: 24338-018
Product information
NDC: 24338-018
Description
MYHIBBIN (mycophenolate mofetil) is an antimetabolite immunosuppressant. It is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.
The chemical name for mycophenolate mofetil (MMF) is 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-,2-(4-morpholinyl) ethyl ester, (E)-. It has an empirical formula of C23H31NO7, a molecular weight of 433.49, and the following structural formula:
MMF is a white or almost white, crystalline powder. It is slightly soluble in water (43 µg/mL at pH 7.4); the solubility increases in acidic medium (4.27 mg/mL at pH 3.6).
The drug product is an oral suspension that contains 200 mg of mycophenolate mofetil/mL. The pH of suspension is between 6 and 8.
Inactive ingredients in MYHIBBIN include dibasic sodium phosphate, glycerin, methylparaben, monobasic sodium phosphate, polysorbate 80, propylparaben, purified water, raspberry flavor, simethicone emulsion, sorbitol solution, and xanthan gum.
Structure
Indications
MYHIBBIN is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney
[see
Clinical Studies (14.1) ],
heart
[see
Clinical Studies (14.2) ]
or liver transplants
[see
Clinical Studies (14.3) ]
, in combination with other immunosuppressants.
MYHIBBIN is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. (
1 )
Dosage
ADULTS
DOSAGE
Kidney Transplant
1 g orally twice daily (
2.2 )
Heart Transplant
1.5 g orally twice daily (
2.3 )
Liver Transplant
1.5 g orally twice daily (
2.4 )
PEDIATRICS
Kidney Transplant
600 mg/m
2 orally twice daily, up to maximum of 2 g daily (
2.2 )
Heart Transplant
600 mg/m
2 orally twice daily (starting dose) up to a maximum of 900 mg/m
2 twice daily (maximum daily dose of 3 g or 15 mL of oral suspension) (
2.3 )
Liver Transplant
600 mg/m
2 orally twice daily (starting dose) up to a maximum of 900 mg/m
2 twice daily (maximum daily dose of 3 g or 15 mL of oral suspension) (
2.4 )
Reduce or interrupt dosing in the event of neutropenia. (
2.5 )
See full prescribing information (FPI) for: dosage modifications for renal impairment and neutropenia (
2.5 )
MYHIBBIN should not be used without the supervision of a physician with experience in immunosuppressive therapy.
MYHIBBIN should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapy because the rates of absorption following the administration of MYHIBBIN and mycophenolic acid delayed-release tablets are not equivalent.
Patients should avoid contact of the skin or mucous membranes with MYHIBBIN. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.
The initial oral dose of MYHIBBIN should be given as soon as possible following kidney, heart or liver transplant. It is recommended that MYHIBBIN be administered on an empty stomach. In stable transplant patients, however, MYHIBBIN may be administered with food if necessary
[see
Clinical Pharmacology (12.3) ].
MYHIBBIN must not be mixed with any liquids prior to dose administration. If needed, MYHIBBIN can be administered via a nasogastric tube with a minimum size of 8 French (minimum 1.7 mm interior diameter).
Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take MYHIBBIN at the usual times.
Adults
The recommended dosage for adult kidney transplant patients is 1 g orally, administered twice daily (total daily dose of 2 g).
Pediatrics Patients 3 months and older
Pediatric dosing is based on body surface area (BSA). The recommended dosage for pediatric kidney transplant patients 3 months and older is 600 mg/m
2 , administered twice daily (maximum daily dose of 2 g or 10 mL of the oral suspension).
Adults
The recommended dosage for adult heart transplant patients is 1.5 g orally administered twice daily (total daily dose of 3 g).
Pediatric Patients 3 months and older
The recommended starting dosage for pediatric heart transplant patients 3 months and older is 600 mg/m
2 , administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m
2 administered twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.
Adults
The recommended dosage for adult liver transplant patients is 1.5 g administered orally twice daily (total daily dose of 3 g).
Pediatrics Patients 3 months and older
The recommended starting dosage for pediatric liver transplant patients 3 months and older is 600 mg/m
2 , administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m
2 administered twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.
Renal Impairment No dosage modifications are needed in kidney transplant patients with delayed graft function postoperatively [see Clinical Pharmacology (12.3)]. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m
2 ), do not administer doses of MYHIBBIN greater than 1 g twice a day. These patients should be carefully monitored [
see
Clinical Pharmacology (12.3)
].
Neutropenia
If neutropenia develops (ANC <1.3 x 10
3 /µL), dosing with MYHIBBIN should be interrupted or reduced, appropriate diagnostic tests performed, and the patient managed appropriately
[see
Warnings and Precautions (5.4) and
Adverse Reactions (6.1) ].
Dosage forms
Oral suspension: mycophenolate mofetil 200 mg/mL in a white to off-white suspension.
Oral Suspension: 200 mg/mL mycophenolate mofetil.
Contraindications
Allergic reactions to mycophenolate mofetil have been observed; therefore, MYHIBBIN is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (MMF), mycophenolic acid (MPA), polysorbate 80 (TWEEN) or any other component of the drug product.
Hypersensitivity to mycophenolate mofetil, mycophenolic acid, polysorbate 80 or any component of the drug product (
4 )
Warnings
Blood Dyscrasias (Neutropenia, Red Blood Cell Aplasia): Monitor with blood tests; consider treatment interruption or dose reduction. (
5.4 )
Gastrointestinal Complications: Monitor for complications such as bleeding, ulceration and perforations, particularly in patients with underlying gastrointestinal disorders. (
5.5 )
Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency: Avoid use of MYHIBBIN. (
5.6 )
Acute Inflammatory Syndrome Associated with Mycophenolate Products: Monitor for this paradoxical inflammatory reaction. (
5.7 )
Immunizations: Avoid live attenuated vaccines. (
5.8 )
Blood Donation: Avoid during therapy and for 6 weeks thereafter. (
5.9 )
Semen Donation: Avoid during therapy and for 90 days thereafter. (
5.10 )
Potential Impairment on Driving and Use of Machinery: MYHIBBIN may affect ability to drive or operate machinery. (
5.12 )
Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney and nervous system. Females of reproductive potential must be made aware of these risks and must be counseled regarding pregnancy prevention and planning. Avoid use of MYHIBBIN during pregnancy if safer treatment options are available
[see
Use in Specific Populations (8.1 ,
8.3) ].
Patients receiving immunosuppressants, including MYHIBBIN, are at increased risk of developing lymphomas and other malignancies, particularly of the skin
[see
Adverse Reactions (6.1) ].
The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. For patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a broad-spectrum sunscreen with a high protection factor.
Post-transplant lymphoproliferative disorder (PTLD) developed in 0.4% to 1% of patients receiving mycophenolate mofetil (2 g or 3 g) with other immunosuppressive agents in controlled clinical trials of kidney, heart and liver transplant patients
[see
Adverse Reactions (6.1) ].
The majority of PTLD cases appear to be related to Epstein Barr Virus (EBV) infection. The risk of PTLD appears greatest in those individuals who are EBV seronegative, a population which includes many young children. In pediatric patients, no other malignancies besides PTLD were observed in clinical trials
[see
Adverse Reactions (6.1) ].
Patients receiving immunosuppressants, including MYHIBBIN, are at increased risk of developing bacterial, fungal, protozoal and new or reactivated viral infections, including opportunistic infections. The risk increases with the total immunosuppressive load. These infections may lead to serious outcomes, including hospitalizations and death
[see
Adverse Reactions (6.1 ,
6.2) ].
Serious viral infections reported include:
Polyomavirus-associated nephropathy (PVAN), especially due to BK virus infection
JC virus-associated progressive multifocal leukoencephalopathy (PML), and
Cytomegalovirus (CMV) infections: CMV seronegative transplant patients who receive an organ from a CMV seropositive donor are at highest risk of CMV viremia and CMV disease.
Viral reactivation in patients infected with Hepatitis B and C
COVID-19
Consider dose reduction or discontinuation of MYHIBBIN in patients who develop new infections or reactivate viral infections, weighing the risk that reduced immunosuppression represents to the functioning allograft.
PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal graft loss
[see
Adverse Reactions (6.2) ].
Patient monitoring may help detect patients at risk for PVAN.
PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia
[see
Adverse Reactions (6.2) ]
. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms.
The risk of CMV viremia and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease.
Viral reactivation has been reported in patients infected with HBV or HCV. Monitoring infected patients for clinical and laboratory signs of active HBV or HCV infection is recommended.
Severe neutropenia [absolute neutrophil count (ANC) <0.5 x 10
3 /µL] developed in transplant patients receiving MMF 3 g daily
[see
Adverse Reactions (6.1) ].
Patients receiving MYHIBBIN should be monitored for neutropenia
. Neutropenia has been observed most frequently in the period from 31 to 180 days post-transplant in patients treated for prevention of kidney, heart and liver rejection. The development of neutropenia may be related to MYHIBBIN itself, concomitant medications, viral infections, or a combination of these causes. If neutropenia develops (ANC <1.3 x 10
3 /µL), dosing with MYHIBBIN should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately
[see
Dosage and Administration (2.5) ].
Patients receiving MYHIBBIN should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
Consider monitoring with complete blood counts weekly for the first month, twice monthly for the second and third months, and monthly for the remainder of the first year.
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with MMF in combination with other immunosuppressive agents. In some cases, PRCA was found to be reversible with dose reduction or cessation of MMF therapy. In transplant patients, however, reduced immunosuppression may place the graft at risk.
Gastrointestinal bleeding requiring hospitalization, ulceration and perforations were observed in clinical trials. Physicians should be aware of these serious adverse effects particularly when administering MYHIBBIN to patients with a gastrointestinal disease.
Mycophenolate mofetil is an inosine monophosphate dehydrogenase (IMPDH) inhibitor; therefore it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.
Acute inflammatory syndrome (AIS) has been reported with the use of MMF and mycophenolate products, and some cases have resulted in hospitalization. AIS is a paradoxical pro-inflammatory reaction characterized by fever, arthralgias, arthritis, muscle pain and elevated inflammatory markers including, C-reactive protein and erythrocyte sedimentation rate, without evidence of infection or underlying disease recurrence. Symptoms occur within weeks to months of initiation of treatment or a dose increase. After discontinuation, improvement of symptoms and inflammatory markers are usually observed within 24 to 48 hours.
Monitor patients for symptoms and laboratory parameters of AIS when starting treatment with mycophenolate products or when increasing the dosage. Discontinue treatment and consider other treatment alternatives based on the risk and benefit for the patient.
During treatment with MYHIBBIN, the use of live attenuated vaccines should be avoided (e.g., intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines) and patients should be advised that vaccinations may be less effective. Advise patients to discuss with the physician before seeking any immunizations.
Patients should not donate blood during therapy and for at least 6 weeks following discontinuation of MYHIBBIN because their blood or blood products might be administered to a female of reproductive potential or a pregnant woman.
Based on animal data, men should not donate semen during therapy and for 90 days following discontinuation of MYHIBBIN
[see
Use In Specific Populations (8.3) ]
.
A variety of drugs have potential to alter systemic MPA exposure when co-administered with MYHIBBIN. Therefore, determination of MPA concentrations in plasma before and after making any changes to immunosuppressive therapy, or when adding or discontinuing concomitant medications, may be appropriate to ensure MPA concentrations remain stable.
MYHIBBIN may impact the ability to drive and use machines. Patients should avoid driving or using machines if they experience somnolence, confusion, dizziness, tremor, or hypotension during treatment with MYHIBBIN
[see
Adverse Reactions (6.1) ]
.
Adverse reactions
The following adverse reactions are discussed in greater detail in other sections of the label:
Drug interactions
See FPI for drugs that may interfere with systemic exposure and reduce MYHIBBIN efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (
7.1 )
MYHIBBIN may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (
7.2 )
See FPI for other important drug interactions. (
7 )
Table 3 Drug Interactions with MYHIBBIN that Affect Mycophenolic Acid (MPA) Exposure
Antacids with Magnesium or Aluminum Hydroxide
Clinical Impact
Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure
[see
Clinical Pharmacology (12.3) ]
, which may reduce MYHIBBIN efficacy.
Prevention or Management
Administer magnesium or aluminum hydroxide containing antacids at least 2h after MYHIBBIN.
Proton Pump Inhibitors (PPIs)
Clinical Impact
Concomitant use with PPIs decreases MPA systemic exposure
[see
Clinical Pharmacology (12.3) ]
, which may reduce MYHIBBIN efficacy.
Prevention or Management
Monitor patients for alterations in efficacy when PPIs are co- administered with MYHIBBIN.
Examples
Lansoprazole, pantoprazole
Drugs that Interfere with Enterohepatic Recirculation
Clinical Impact
Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure
[see
Clinical Pharmacology (12.3) ]
, which may reduce MYHIBBIN efficacy.
Prevention or Management
Monitor patients for alterations in efficacy or MYHIBBIN-related adverse reactions when these drugs are co-administered with MYHIBBIN.
Examples
Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials
Drugs Modulating Glucuronidation
Clinical Impact
Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing MYHIBBIN efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure
[see
Clinical Pharmacology (12.3) ]
, which may increase the risk of MYHIBBIN-related adverse reactions.
Prevention or Management
Monitor patients for alterations in efficacy or MYHIBBIN-related adverse reactions when these drugs are co-administered with MYHIBBIN.
Examples
Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation).
Calcium Free Phosphate Binders
Clinical Impact
Concomitant use with calcium free phosphate binders decrease MPA systemic exposure
[see
Clinical Pharmacology (12.3) ]
, which may reduce MYHIBBIN efficacy.
Prevention or Management
Administer calcium free phosphate binders at least 2 hours after MYHIBBIN.
Examples
Sevelamer
Table 4 Drug Interactions with MYHIBBIN that Affect Other Drugs
Drugs that Undergo Renal Tubular Secretion
Clinical Impact
When concomitantly used with MYHIBBIN, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs.
Prevention or Management
Monitor for drug-related adverse reactions in patients with renal impairment.
Examples
Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir
Combination Oral Contraceptives
Clinical Impact
Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol
[see
Clinical Pharmacology (12.3) ]
, which may result in reduced combination oral contraceptive effectiveness.
Prevention or Management
Use additional barrier contraceptive methods.
Use in_specific_populations
Male Patients: Sexually active male patients and/or their female partners are recommended to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment (
8.3 )
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing MYHIBBIN treatment. To report a pregnancy or obtain information about the registry, visit the Mycophenolate Pregnancy Registry at www.mycophenolateREMS.com or call 1-800-617-8191.
Risk Summary Use of mycophenolate mofetil (MMF) during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of multiple congenital malformations in multiple organ systems (see Human Data). Oral administration of mycophenolate to rats and rabbits during the period of organogenesis produced congenital malformations and pregnancy loss at doses less than the recommended clinical dose (0.01 to 0.05 times the recommended clinical doses in kidney and heart transplant patients) (see Animal Data). Consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of MYHIBBIN should be discussed with the pregnant woman. The background risk of pregnancy loss and congenital malformations in organ transplant populations is not clear. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Human Data
A spectrum of congenital malformations (including multiple malformations in individual newborns) has been reported in 23 to 27% of live births in MMF exposed pregnancies, based on published data from pregnancy registries. Malformations that have been documented include external ear, eye, and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system.
Based on published data from pregnancy registries, the risk of first trimester pregnancy loss has been reported at 45 to 49% following MMF exposure.
Animal Data
In animal reproductive toxicology studies, there were increased rates of fetal resorptions and malformations in the absence of maternal toxicity. Oral administration of MMF to pregnant rats from Gestational Day 7 to Day 16 produced increased embryofetal lethality and fetal malformations including anophthalmia, agnathia, and hydrocephaly at doses equivalent to 0.015 and 0.01 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA. Oral administration of MMF to pregnant rabbits from Gestational Day 7 to Day 19 produced increased embryofetal lethality and fetal malformations included ectopia cordis, ectopic kidneys, diaphragmatic hernia, and umbilical hernia at dose equivalents as low as 0.05 and 0.03 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA.
Risk Summary There are no data on the presence of mycophenolate in human milk, or the effects on milk production. There are limited data in the National Transplantation Pregnancy Registry on the effects of mycophenolate on a breastfed child (see Data). Studies in rats treated with MMF have shown mycophenolic acid (MPA) to be present in milk. Because available data are limited, it is not possible to exclude potential risks to a breastfeeding infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MYHIBBIN and any potential adverse effects on the breastfed infant from MYHIBBIN or from the underlying maternal condition.
Data Limited information is available from the National Transplantation Pregnancy Registry. Of seven infants reported by the National Transplantation Pregnancy Registry to have been breastfed while the mother was taking mycophenolate, all were born at 34-40 weeks gestation, and breastfed for up to 14 months. No adverse events were reported.
Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.
Pregnancy Planning
For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity whenever possible. Risks and benefits of MYHIBBIN should be discussed with the patient.
Pregnancy Testing
To prevent unplanned exposure during pregnancy, all females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mlU/mL immediately before starting MYHIBBIN. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient. In the event of a positive pregnancy test, consider alternative immunosuppressants with less potential for embryofetal toxicity whenever possible.
Contraception
Female Patients
Females of reproductive potential taking MYHIBBIN must receive contraceptive counseling and use acceptable contraception (see
Table 5
for acceptable contraception methods). Patients must use acceptable birth control during the entire MYHIBBIN therapy, and for 6 weeks after stopping MYHIBBIN, unless the patient chooses abstinence.
Patients should be aware that MYHIBBIN reduces blood levels of the hormones from the oral contraceptive pill and could theoretically reduce its effectiveness
[see
Drug Interactions (7.2) ].
Table 5 Acceptable Contraception Methods for Females of Reproductive Potential Pick from the following birth control options:
Option 1
Methods to Use Alone
Intrauterine devices (IUDs)
Tubal sterilization
Patient’s partner vasectomy
OR
Option 2
Hormone Methods
choose 1
Barrier Methods
choose 1
Choose One Hormone Method
AND
One Barrier Method
Estrogen and Progesterone
Oral Contraceptive Pill
Transdermal patch
Vaginal ring
Progesterone-only
Injection
Implant
AND
Diaphragm with spermicide
Cervical cap with spermicide
Contraceptive sponge
Male condom
Female condom
OR
Option 3
Barrier Methods
choose 1
Barrier Methods
choose 1
Choose One Barrier Method from each column
(must choose two methods)
Diaphragm with spermicide
Cervical cap with spermicide
Contraceptive sponge
AND
Male condom
Female condom
Male Patients Genotoxic effects have been observed in animal studies at exposures exceeding the human therapeutic exposures by approximately 1.25 times. Thus, the risk of genotoxic effects on sperm cells cannot be excluded. Based on this potential risk, sexually active male patients and/or their female partners are recommended to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment. Also, based on the potential risk of genotoxic effects, male patients should not donate sperm during treatment with MYHIBBIN and for at least 90 days after cessation of treatment [
see
Use in Special Populations (8.1) ,
Nonclinical Toxicology (13.1) ,
Patient Counseling Information (17.9)
].
Safety and effectiveness have been established in pediatric patients 3 months and older for the prophylaxis of organ rejection of allogenic kidney, heart or liver transplants.
Kidney Transplant
Use of MYHIBBIN in this population is supported by evidence from adequate and well-controlled studies of mycophenolate mofetil in adults with additional data from one open-label, pharmacokinetic and safety study of mycophenolate mofetil in pediatric patients after receiving allogeneic kidney transplant (100 patients, 3 months to 18 years of age)
[see
Dosage and Administration (2.2) ,
Adverse Reactions (6.1) ,
Clinical Pharmacology (12.3) ,
Clinical Studies (14.1) ].
Heart Transplant and Liver Transplant
Use of MYHIBBIN in pediatric heart transplant and liver transplant patients is supported by adequate and well-controlled studies and pharmacokinetic data in adult heart transplant and liver transplant patients. Additional supportive data include pharmacokinetic data in pediatric kidney transplant and pediatric liver transplant patients (8 liver transplant patients, 9 months to 5 years of age, in an open-label, pharmacokinetic and safety study) and published evidence of clinical efficacy and safety in pediatric heart transplant and pediatric liver transplant patients
[see
Dosage and Administration (2.3 ,
2.4) ,
Adverse Reactions (6.1) ,
Clinical Pharmacology (12.3) ,
Clinical Studies (14.1) ].
The combination of inactive ingredients (e.g., simethicone, sodium phosphate monobasic dihydrate, sodium phosphate dibasic dihydrate, glycerin) in MYHIBBIN have the potential to impact gastrointestinal tolerability. Monitor pediatric patients receiving MYHIBBIN for signs and symptoms of gastrointestinal intolerance.
Clinical studies of mycophenolate mofetil did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between geriatric and younger patients. In general, dose selection for a geriatric patient should take into consideration the presence of decreased hepatic, renal or cardiac function and of concomitant drug therapies.
[see
Adverse Reactions (6.1) ,
Drug Interactions (7) ].
Patients with Kidney Transplant No dosage adjustments are needed in kidney transplant patients experiencing delayed graft function postoperatively, but patients should be carefully monitored [
see
Clinical Pharmacology (12.3)
]. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m
2 ), no dose adjustments are necessary; however, doses greater than 1 g administered twice a day should be avoided.
Patients with Heart and Liver Transplant
No data are available for heart or liver transplant patients with severe chronic renal impairment. MYHIBBIN may be used for heart or liver transplant patients with severe chronic renal impairment if the potential benefits outweigh the potential risks.
Patients with Kidney Transplant
No dosage adjustments are recommended for kidney transplant patients with severe hepatic parenchymal disease. However, it is not known whether dosage adjustments are needed for hepatic disease with other etiologies
[see
Clinical Pharmacology (12.3) ].
Patients with Heart Transplant No data are available for heart transplant patients with severe hepatic parenchymal disease.
How supplied
Handling and Disposal
Mycophenolate mofetil has demonstrated teratogenic effects in humans
[see
Warnings and Precautions (5.1) and
Use in Specific Populations (8.1) ]
. Wearing disposable gloves is recommended when wiping the outer surface of the bottle and or bottle cap. Avoid direct contact of MYHIBBIN with skin or mucous membranes
[see
Dosage and Administration (2.6) ].
Follow applicable special handling and disposal procedures
1 .
Do not use after 60 days of first opening the bottle.
MYHIBBIN is supplied as a white to off-white oral suspension of mycophenolate mofetil 200 mg/mL and it is supplied with a child resistant cap:
175 mL of suspension in 225 mL bottle.............................................. NDC 24338-018-01
Storage and Stability
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].
Do not freeze.
Clinical pharmacology
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the
de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4+ T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28.
MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-Ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.
Overall, the effect of MPA is cytostatic and reversible.
There is a lack of information regarding the pharmacodynamic effects of MMF.
Absorption
Following oral administration, MMF undergoes complete conversion to MPA, the active metabolite. In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%.
The mean (±SD) pharmacokinetic parameters estimates for MPA following the administration of MMF given as single doses to healthy volunteers, and multiple doses to kidney, heart, and liver transplant patients, are shown in
Table 6
. The area under the plasma-concentration time curve (AUC) for MPA appears to increase in a dose-proportional fashion in kidney transplant patients receiving multiple oral doses of MMF up to a daily dose of 3 g (1.5g twice daily) (see
Table 6
).
Table 6 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Administration of MMF to Healthy Volunteers (Single Dose), and Kidney, Heart, and Liver Transplant Patients (Multiple Doses)
Healthy Volunteers
Dose/Route
T
max
(h)
C
max
(mcg/mL)
Total AUC
(mcg∙h/mL)
Single dose
1 g/oral
0.80
(±0.36)
(n=129)
24.5
(±9.5)
(n=129)
63.9
(±16.2)
(n=117)
Kidney Transplant Patients (twice daily dosing) Time After Transplantation
Dose/Route
T
max
(h)
C
max
(mcg/mL)
Interdosing Interval AUC(0-12h)
(mcg∙h/mL)
5 days
1 g
1.58
(±0.46)
(n=31)
12.0
(±3.82)
(n=31)
40.8
(±11.4)
(n=31)
6 days
1 g/oral
1.33
(±1.05)
(n=31)
10.7
(±4.83)
(n=31)
32.9
(±15.0)
(n=31)
Early (Less than 40 days)
1 g/oral
1.31
(±0.76)
(n=25)
8.16
(±4.50)
(n=25)
27.3
(±10.9)
(n=25)
Early (Less than 40 days)
1.5 g/oral
1.21
(±0.81)
(n=27)
13.5
(±8.18)
(n=27)
38.4
(±15.4)
(n=27)
Late (Greater than 3 months)
1.5 g/oral
0.90
(±0.24)
(n=23)
24.1
(±12.1)
(n=23)
65.3
(±35.4)
(n=23)
Heart Transplant Patients (twice daily dosing) Time After Transplantation
Dose/Route
T
max
(h)
C
max
(mcg/mL)
Interdosing Interval AUC(0-12h)
(mcg∙h/mL)
Early (Day before discharge)
1.5 g/oral
1.8
(±1.3)
(n=11)
11.5
(±6.8)
(n=11)
43.3
(±20.8)
(n=9)
Late (Greater than 6 months)
1.5 g/oral
1.1
(±0.7)
(n=52)
20.0
(±9.4)
(n=52)
54.1
a
(±20.4)
(n=49)
Liver Transplant Patients (twice daily dosing) Time After Transplantation
Dose/Route
T
max
(h)
C
max
(mcg/mL)
Interdosing Interval AUC(0-12h)
(mcg∙h/mL)
4 to 9 days
1 g
1.50
(±0.517)
(n=22)
17.0
(±12.7)
(n=22)
34.0
(±17.4)
(n=22)
Early (5 to 8 days)
1.5 g/oral
1.15
(±0.432)
(n=20)
13.1
(±6.76)
(n=20)
29.2
(±11.9)
(n=20)
Late (Greater than 6 months)
1.5 g/oral
1.54
(±0.51)
(n=6)
19.3
(±11.7)
(n=6)
49.3
(±14.8)
(n=6)
a AUC(0-12h) values quoted are extrapolated from data from samples collected over 4 hours.
In the early post-transplant period (less than 40 days post-transplant), kidney, heart, and liver transplant patients had mean MPA AUCs approximately 20% to 41% lower and mean C
max approximately 32% to 44% lower compared to the late transplant period (i.e., 3 to 6 months post-transplant) (non-stationarity in MPA pharmacokinetics).
In liver transplant patients, administration of 1.5 g twice daily oral MMF resulted in mean MPA AUC estimates similar to those found in kidney transplant patients administered 1 g MMF twice daily.
Effect of Food
Food (27 g fat, 650 calories) had no effect on the extent of absorption (MPA AUC) of MMF when administered at doses of 1.5 g twice daily to kidney transplant patients. However, MPA C
max was decreased by 40% in the presence of food
[see
Dosage and Administration (2.1) ].
Distribution
The mean (±SD) apparent volume of distribution of MPA in 12 healthy volunteers was approximately 3.6 (±1.5) L/kg. At clinically relevant concentrations, MPA is 97% bound to plasma albumin. The phenolic glucuronide metabolite of MPA (MPAG) is 82% bound to plasma albumin at MPAG concentration ranges that are normally seen in stable kidney transplant patients; however, at higher MPAG concentrations (observed in patients with kidney impairment or delayed kidney graft function), the binding of MPA may be reduced as a result of competition between MPAG and MPA for protein binding. Mean blood to plasma ratio of radioactivity concentrations was approximately 0.6 indicating that MPA and MPAG do not extensively distribute into the cellular fractions of blood.
In vitro studies to evaluate the effect of other agents on the binding of MPA to human serum albumin (HSA) or plasma proteins showed that salicylate (at 25 mg/dL with human serum albumin) and MPAG (at ≥ 460 mcg/mL with plasma proteins) increased the free fraction of MPA. MPA at concentrations as high as 100 mcg/mL had little effect on the binding of warfarin, digoxin or propranolol, but decreased the binding of theophylline from 53% to 45% and phenytoin from 90% to 87%.
Elimination
Mean (±SD) apparent half-life and plasma clearance of MPA are 17.9 (±6.5) hours and 193 (±48) mL/min following oral administration.
Metabolism
MPA is metabolized principally by glucuronyl transferase to form MPAG, which is not pharmacologically active.
In vivo , MPAG is converted to MPA during enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of MMF to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)- morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine.
Due to the enterohepatic recirculation of MPAG/MPA, secondary peaks in the plasma MPA concentration-time profile are usually observed 6 to 12 hours post-dose. Bile sequestrants, such as cholestyramine, reduce MPA AUC by interfering with this enterohepatic recirculation of the drug
[see
Overdosage (10) and
Drug Interaction Studies below
].
Excretion
Negligible amount of drug is excreted as MPA (less than 1% of dose) in the urine. Orally administered radiolabeled MMF resulted in complete recovery of the administered dose, with 93% of the administered dose recovered in the urine and 6% recovered in feces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (> 100 mcg/mL), small amounts of MPAG are removed.
Increased plasma concentrations of MMF metabolites (MPA 50% increase and MPAG about a 3-fold to 6-fold increase) are observed in patients with renal insufficiency
[see
Specific Populations ].
Specific Populations
Patients with Renal Impairment
The mean (±SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to non-transplant subjects with renal impairment are presented in
Table 7
.
Plasma MPA AUC observed after oral dosing to volunteers with severe chronic renal impairment (GFR < 25 mL/min/1.73 m
2 ) was about 75% higher relative to that observed in healthy volunteers (GFR > 80 mL/min/1.73 m
2 ). In addition, the single-dose plasma MPAG AUC was 3-fold to 6-fold higher in volunteers with severe renal impairment than in volunteers with mild renal impairment or healthy volunteers, consistent with the known renal elimination of MPAG. No data are available on the safety of long-term exposure to this level of MPAG. Multiple dosing of MMF in patients with severe chronic renal impairment has not been studied.
Patients with Delayed Graft Function or Nonfunction
In patients with delayed renal graft function post-transplant, mean MPA AUC(0-12h) was comparable to that seen in post-transplant patients without delayed renal graft function. There is a potential for a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. However, dose adjustment does not appear to be necessary in patients with delayed renal graft function. Mean plasma MPAG AUC(0-12h) was 2-fold to 3-fold higher than in post-transplant patients without delayed renal graft function
[see
Dosage and Administration (2.5) ].
In eight patients with primary graft non-function following kidney transplantation, plasma concentrations of MPAG accumulated about 6-fold to 8-fold after multiple dosing for 28 days. Accumulation of MPA was about 1-fold to 2-fold.
The pharmacokinetics of MMF are not altered by hemodialysis. Hemodialysis usually does not remove MPA or MPAG. At high concentrations of MPAG (> 100 mcg/mL), hemodialysis removes only small amounts of MPAG.
Patients with Hepatic Impairment
The mean (± SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to non-transplant subjects with hepatic impairment is presented in
Table 7
.
In a single-dose (1 g oral) study of 18 volunteers with alcoholic cirrhosis and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when pharmacokinetic parameters of healthy volunteers and alcoholic cirrhosis patients within this study were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this study had about a 50% lower AUC as compared to healthy volunteers in other studies, thus making comparisons between volunteers with alcoholic cirrhosis and healthy volunteers difficult.
Table 7 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Single Doses of MMF Capsules in Chronic Renal and Hepatic Impairment
Pharmacokinetic Parameters for Renal Impairment
Dose
T
max
(h)
C
max
(mcg/mL)
AUC(0-96h)
(mcg∙h/mL)
Healthy Volunteers
GFR greater than 80 mL/min/1.73 m
2
(n=6)
1 g
0.75
(±0.27)
25.3
(±7.99)
45.0
(±22.6)
Mild Renal Impairment
GFR 50 to 80 mL/min/1.73 m
2
(n=6)
1 g
0.75
(±0.27)
26.0
(±3.82)
59.9
(±12.9)
Moderate Renal Impairment
GFR 25 to 49 mL/min/1.73 m
2
(n=6)
1 g
0.75
(±0.27)
19.0
(±13.2)
52.9
(±25.5)
Severe Renal Impairment
GFR less than 25 mL/min/1.73 m
2
(n=7)
1 g
1.00
(±0.41)
16.3
(±10.8)
78.6
(±46.4)
Pharmacokinetic Parameters for Hepatic Impairment
Dose
T
max
(h)
C
max
(mcg/mL)
AUC(0-48h)
(mcg∙h/mL)
Healthy Volunteers
(n=6)
1 g
0.63
(±0.14)
24.3
(±5.73)
29.0
(±5.78)
Alcoholic Cirrhosis
(n=18)
1 g
0.85
(±0.58)
22.4
(±10.1)
29.8
(±10.7)
Pediatric Patients
The pharmacokinetic parameters of MPA and MPAG have been evaluated in 55 pediatric patients (ranging from 1 year to 18 years of age) receiving MMF oral suspension at a dose of 600 mg/m
2 twice daily (up to a maximum of 1 g twice daily) after allogeneic kidney transplantation. The pharmacokinetic data for MPA is provided in
Table 8
.
Table 8 Mean (±SD) Computed Pharmacokinetic Parameters for MPA by Age and Time After Allogeneic Kidney Transplantation
Age Group
(n)
Time
T
max
(h)
Dose Adjusted
a C
max
(mcg/mL)
Dose Adjusted
a AUC
0-12
(mcg∙h/mL)
Early (Day 7)
1 to less than 2 yr
(6)
d
3.03
(4.70)
10.3
(5.80)
22.5
(6.66)
1 to less than 6 yr
(17)
1.63
(2.85)
13.2
(7.16)
27.4
(9.54)
6 to less than 12 yr
(16)
0.940
(0.546)
13.1
(6.30)
33.2
(12.1)
12 to 18 yr
(21)
1.16
(0.830)
11.7
(10.7)
26.3
(9.14)
b
Late (Month 3)
1 to less than 2 yr
(4)
d
0.725
(0.276)
23.8
(13.4)
47.4
(14.7)
1 to less than 6 yr
(15)
0.989
(0.511)
22.7
(10.1)
49.7
(18.2)
6 to less than 12 yr
(14)
1.21
(0.532)
27.8
(14.3)
61.9
(19.6)
12 to 18 yr
(17)
0.978
(0.484)
17.9
(9.57)
53.6
(20.3)
c
Late (Month 9)
1 to less than 2 yr
(4)
d
0.604
(0.208)
25.6
(4.25)
55.8
(11.6)
1 to less than 6 yr
(12)
0.869
(0.479)
30.4
(9.16)
61.0
(10.7)
6 to less than 12 yr
(11)
1.12
(0.462)
29.2
(12.6)
66.8
(21.2)
12 to 18 yr
(14)
1.09
(0.518)
18.1
(7.29)
56.7
(14.0)
a adjusted to a dose of 600 mg/m
2
b n=20
c n=16
d a subset of 1 to < 6 yr
The MMF oral suspension dose of 600 mg/m
2 twice daily (up to a maximum of 1 g twice daily) achieved mean MPA AUC values in pediatric patients similar to those seen in adult kidney transplant patients receiving oral doses of 1 g twice daily in the early post-transplant period. There was wide variability in the data. As observed in adults, early post-transplant MPA AUC values were approximately 45% to 53% lower than those observed in the later post-transplant period (>3 months). MPA AUC values were similar in the early and late post-transplant period across the 1 to 18-year age range.
A comparison of dose-normalized (to 600 mg/m
2 ) MPA AUC values in 12 pediatric kidney transplant patients less than 6 years of age at 9 months post-transplant with those values in 7 pediatric liver transplant patients [median age 17 months (range: 10 – 60 months)] and at 6 months and beyond post-transplant revealed that, at the same dose, there were on average 23% lower AUC values in the pediatric liver compared to pediatric kidney patients. This is consistent with the need for higher dosing in adult liver transplant patients compared to kidney transplant patients to achieve the same exposure.
In adult transplant patients administered the same dosage of MMF, there is similar MPA exposure among kidney transplant and heart transplant patients. Based on the established similarity in MPA exposure between pediatric kidney transplant and adult kidney transplant patients at their respective approved doses, it is expected that MPA exposure at the recommended dosage will be similar in pediatric heart transplant and adult heart transplant patients.
Male and Female Patients
Data obtained from several studies were pooled to look at any gender-related differences in the pharmacokinetics of MPA (data were adjusted to 1 g oral dose). Mean (±SD) MPA AUC (0-12h) for males (n=79) was 32.0 (±14.5) and for females (n=41) was 36.5 (±18.8) mcg∙h/mL while mean (±SD) MPA C
max was 9.96 (±6.19) in the males and 10.6 (±5.64) mcg/mL in the females. These differences are not of clinical significance.
Geriatric Patients
The pharmacokinetics of MMF and its metabolites have not been found to be altered in geriatric transplant patients when compared to younger transplant patients.
Drug Interaction Studies
Acyclovir
Coadministration of MMF (1 g) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and C
max . However, MPAG and acyclovir plasma AUCs were increased 10.6% and 21.9%, respectively.
Antacids with Magnesium and Aluminum Hydroxides
Absorption of a single dose of MMF (2 g) was decreased when administered to 10 rheumatoid arthritis patients also taking Maalox
® TC (10 mL qid). The C
max and AUC(0-24h) for MPA were 33% and 17% lower, respectively, than when MMF was administered alone under fasting conditions.
Proton Pump Inhibitors (PPIs)
Coadministration of PPIs (e.g., lansoprazole, pantoprazole) in single doses to healthy volunteers and multiple doses to transplant patients receiving MMF has been reported to reduce the exposure to MPA. An approximate reduction of 30 to 70% in the C
max and 25% to 35% in the AUC of MPA has been observed, possibly due to a decrease in MPA solubility at an increased gastric pH.
Cholestyramine
Following single-dose administration of 1.5 g MMF to 12 healthy volunteers pretreated with 4 g three times a day of cholestyramine for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine.
Cyclosporine
Cyclosporine (Sandimmune
® ) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 g twice daily of MMF in 10 stable kidney transplant patients. The mean (±SD) AUC(0-12h) and C
max of cyclosporine after 14 days of multiple doses of MMF were 3290 (±822) ng∙h/mL and 753 (±161) ng/mL, respectively, compared to 3245 (±1088) ng∙h/mL and 700 (±246) ng/mL, respectively, 1 week before administration of MMF.
Cyclosporine A interferes with MPA enterohepatic recirculation. In kidney transplant patients, mean MPA exposure (AUC(0-12h)) was approximately 30-50% greater when MMF was administered without cyclosporine compared with when MMF was coadministered with cyclosporine. This interaction is due to cyclosporine inhibition of multidrug-resistance-associated protein 2 (MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic recirculation of MPA. This information should be taken into consideration when MMF is used without cyclosporine.
Drugs Affecting Glucuronidation
Concomitant administration of drugs inhibiting glucuronidation of MPA may increase MPA exposure (e.g., increase of MPA AUC (0-∞) by 35% was observed with concomitant administration of isavuconazole).
Concomitant administration of telmisartan and MMF resulted in an approximately 30% decrease in MPA concentrations. Telmisartan changes MPA's elimination by enhancing PPAR gamma (peroxisome proliferator- activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and glucuronidation activity.
Ganciclovir
Following single-dose administration to 12 stable kidney transplant patients, no pharmacokinetic interaction was observed between MMF (1.5 g) and intravenous ganciclovir (5 mg/kg). Mean (±SD) ganciclovir AUC and C
max (n=10) were 54.3 (±19.0) mcg∙h/mL and 11.5 (±1.8) mcg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) mcg∙h/mL and 10.6 (±2.0) mcg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (±SD) AUC and C
max of MPA (n=12) after coadministration were 80.9 (±21.6) mcg∙h/mL and 27.8 (±13.9) mcg/mL, respectively, compared to values of 80.3 (±16.4) µg∙h/mL and 30.9 (±11.2) mcg/mL, respectively, after administration of MMF alone.
Oral Contraceptives
A study of coadministration of MMF (1 g twice daily) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) was conducted in 18 women with psoriasis over 3 consecutive menstrual cycles. Mean serum levels of LH, FSH and progesterone were not significantly affected. Mean AUC(0-24h) was similar for ethinylestradiol and 3-keto desogestrel; however, mean levonorgestrel AUC(0-24h) significantly decreased by about 15%. There was large inter-patient variability (%CV in the range of 60% to 70%) in the data, especially for ethinylestradiol.
Sevelamer
Concomitant administration of sevelamer and MMF in adult and pediatric patients decreased the mean MPA C
max and AUC (0-12h) by 36% and 26% respectively.
Antimicrobials
Antimicrobials eliminating beta-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antimicrobials) may interfere with the MPAG/MPA enterohepatic recirculation thus leading to reduced systemic MPA exposure. Information concerning antibiotics is as follows:
Trimethoprim/Sulfamethoxazole: Following single-dose administration of MMF (1.5 g) to 12 healthy male volunteers on day 8 of a 10-day course of trimethoprim 160 mg/sulfamethoxazole 800 mg administered twice daily, no effect on the bioavailability of MPA was observed. The mean (±SD) AUC and C
max of MPA after concomitant administration were 75.2 (±19.8) mcg∙h/mL and 34.0 (±6.6) µg/mL, respectively, compared to 79.2 (±27.9) mcg∙h/mL and 34.2 (±10.7) mcg/mL, respectively, after administration of MMF alone.
Norfloxacin and Metronidazole: Following single-dose administration of MMF (1 g) to 11 healthy volunteers on day 4 of a 5-day course of a combination of norfloxacin and metronidazole, the mean MPA AUC(0-48h) was significantly reduced by 33% compared to the administration of MMF alone (p<0.05). The mean (±SD) MPA AUC(0-48h) after coadministration of MMF with norfloxacin or metronidazole separately was 48.3 (±24) mcg∙h/mL and 42.7 (±23) mcg∙h/mL, respectively, compared with 56.2 (±24) mcg∙h/mL after administration of MMF alone.
Ciprofloxacin and Amoxicillin Plus Clavulanic Acid
: A total of 64 MMF -treated kidney transplant recipients received either oral ciprofloxacin 500 mg twice daily or amoxicillin plus clavulanic acid 375 mg three times daily for 7 or at least 14 days, respectively. Approximately 50% reductions in median trough MPA concentrations (pre-dose) from baseline (MMF alone) were observed in 3 days following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antimicrobial therapy and ceased within 3 days of discontinuation of antibiotics.
Rifampin: In a single heart-lung transplant patient, after correction for dose, a 67% decrease in MPA exposure (AUC(0-12h)) has been observed with concomitant administration of MMF and rifampin.
Nonclinical toxicology
In a 104-week oral carcinogenicity study in mice, MMF in daily doses up to 180 mg/kg was not tumorigenic. The highest dose tested was 0.2 times the recommended clinical dose (2 g/day) in renal transplant patients and 0.15 times the recommended clinical dose (3 g/day) in cardiac transplant patients when corrected for differences in body surface area (BSA). In a 104-week oral carcinogenicity study in rats, MMF in daily doses up to 15 mg/kg was not tumorigenic. The highest dose was 0.035 times the recommended clinical dose in kidney transplant patients and 0.025 times the recommended clinical dose in heart transplant patients when corrected for BSA. While these animal doses were lower than those given to patients, they were maximal in those species and were considered adequate to evaluate the potential for human risk
[see
Warnings and Precautions (5.2) ].
The genotoxic potential of MMF was determined in five assays. MMF was genotoxic in the mouse lymphoma/thymidine kinase assay and the
in vivo mouse micronucleus assay. MMF was not genotoxic in the bacterial mutation assay, the yeast mitotic gene conversion assay or the Chinese hamster ovary cell chromosomal aberration assay.
MMF had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. This dose represents 0.05 times the recommended clinical dose in renal transplant patients and 0.03 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (principally of the head and eyes) in the first generation offspring in the absence of maternal toxicity. This dose was 0.01 times the recommended clinical dose in renal transplant patients and 0.005 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.
Clinical studies
Adults
The three
de novo kidney transplantation studies compared two dose levels of oral mycophenolate mofetil (1 g twice daily and 1.5 g twice daily) with azathioprine (2 studies) or placebo (1 study) to prevent acute rejection episodes. One of the two studies with azathioprine (AZA) control arm also included anti-thymocyte globulin (ATGAM
® ) induction therapy. The geographic location of the investigational sites of these studies are included in
Table 9
.
In all three
de novo kidney transplantation studies, the primary efficacy endpoint was the proportion of patients in each treatment group who experienced treatment failure within the first 6 months after transplantation. Treatment failure was defined as biopsy-proven acute rejection on treatment or the occurrence of death, graft loss or early termination from the study for any reason without prior biopsy-proven rejection.
Mycophenolate mofetil, in combination with corticosteroids and cyclosporine, reduced (statistically significant at 0.05 level) the incidence of treatment failure within the first 6 months following transplantation (
Table 9 ).
Patients who prematurely discontinued treatment were followed for the occurrence of death or graft loss, and the cumulative incidence of graft loss and patient death combined are summarized in
Table 10
. Patients who prematurely discontinued treatment were not followed for the occurrence of acute rejection after termination.
Table 9 Treatment Failure in De Novo Kidney Transplantation Studies
*Does not include death and graft loss as reason for early termination.
USA Study
MYCOPHENOLATE MOFETIL
2 g/day
MYCOPHENOLATE MOFETIL
3 g/day
AZA
1 to 2 mg/kg/day
(N=499 patients)
(n=167 patients)
(n=166 patients)
(n=166 patients)
All 3 groups received anti-thymocyte globulin induction, cyclosporine and corticosteroids
All treatment failures
31.1%
31.3%
47.6%
Early termination without prior acute rejection
9.6%
12.7%
6.0%
Biopsy-proven rejection episode on treatment
19.8%
17.5%
38.0%
Europe/Canada/Australia Study
(N=503 patients)
MYCOPHENOLATE MOFETIL
2 g/day
(n=173 patients)
MYCOPHENOLATE MOFETIL
3 g/day
(n=164 patients)
AZA
100 to 150 mg/day
(n=166 patients)
No induction treatment administered; all 3 groups received cyclosporine and corticosteroids.
All treatment failures
38.2%
34.8%
50.0%
Early termination without prior acute rejection
13.9%
15.2%
10.2%
Biopsy-proven rejection episode on treatment
19.7%
15.9%
35.5%
Europe Study
MYCOPHENOLATE MOFETIL
2 g/day
MYCOPHENOLATE MOFETIL
3 g/day
Placebo
(N=491 patients)
(n=165 patients)
(n=160 patients)
(n=166 patients)
No induction treatment administered; all 3 groups received cyclosporine and corticosteroids.
All treatment failures
30.3%
38.8%
56.0%
Early termination without prior acute rejection
11.5%
22.5%
7.2%
Biopsy-proven rejection episode on treatment
17.0%
13.8%
46.4%
No advantage of mycophenolate mofetil at 12 months with respect to graft loss or patient death (combined) was established (
Table 10
). Numerically, patients receiving mycophenolate mofetil 2 g/day and 3 g/day experienced a better outcome than controls in all three studies; patients receiving mycophenolate mofetil 2 g/day experienced a better outcome than mycophenolate mofetil 3 g/day in two of the three studies. Patients in all treatment groups who terminated treatment early were found to have a poor outcome with respect to graft loss or patient death at 1 year.
Table 10 De Novo Kidney Transplantation Studies Cumulative Incidence of Combined Graft Loss or Patient Death at 12 Months
Study
MYCOPHENOLATE MOFETIL 2 g/day
MYCOPHENOLATE MOFETIL 3 g/day
Control
(AZA or Placebo)
USA
8.5%
11.5%
12.2%
Europe/Canada/Australia
11.7%
11.0%
13.6%
Europe
8.5%
10.0%
11.5%
Pediatrics- De Novo Kidney transplantation PK Study with Long Term Follow-Up One open-label, safety and pharmacokinetic study of mycophenolate mofetil oral suspension 600 mg/m
2 twice daily (up to 1 g twice daily) in combination with cyclosporine and corticosteroids was performed at centers in the United States (9), Europe (5) and Australia (1) in 100 pediatric patients (3 months to 18 years of age) for the prevention of renal allograft rejection. Mycophenolate mofetil was well tolerated in pediatric patients [see Adverse Reactions (6.1)]. The rate of biopsy-proven rejection was similar across the age groups (3 months to <6 years, 6 years to <12 years, 12 years to 18 years). The overall biopsy-proven rejection rate at 6 months was comparable to adults. The combined incidence of graft loss (5%) and patient death (2%) at 12 months post-transplant was similar to that observed in adult kidney transplant patients.
A double-blind, randomized, comparative, parallel-group, multicenter study in primary
de novo heart transplant recipients was performed at centers in the United States (20), in Canada (1), in Europe (5) and in Australia (2). The total number of patients enrolled (ITT population) was 650; 72 never received study drug and 578 received study drug (Safety Population). Patients received mycophenolate mofetil 1.5 g twice daily (n=289) or AZA 1.5 to 3 mg/kg/day (n=289), in combination with cyclosporine (Sandimmune
® or Neoral
® ) and corticosteroids as maintenance immunosuppressive therapy. The two primary efficacy endpoints were: (1) the proportion of patients who, after transplantation, had at least one endomyocardial biopsy-proven rejection with hemodynamic compromise, or were re-transplanted or died, within the first 6 months, and (2) the proportion of patients who died or were re-transplanted during the first 12 months following transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection for up to 6 months and for the occurrence of death for 1 year.
The analyses of the endpoints showed:
Rejection: No difference was established between mycophenolate mofetil and AZA with respect to biopsy-proven rejection with hemodynamic compromise.
Survival: Mycophenolate mofetil was shown to be at least as effective as AZA in preventing death or re-transplantation at 1 year (see
Table 11
).
Table 11 De Novo Heart Transplantation Study Rejection at 6 Months/Death or Re-transplantation at 1 Year
All Patients (ITT)
Treated Patients
AZA
N = 323
MYCOPHENOLATE MOFETIL
N = 327
AZA
N = 289
MYCOPHENOLATE MOFETIL
N = 289
Biopsy-proven rejection with hemodynamic compromise at 6 months
a
121 (38%)
120 (37%)
100 (35%)
92 (32%)
Death or re-transplantation at 1 year
49 (15.2%)
42 (12.8%)
33 (11.4%)
18 (6.2%)
a Hemodynamic compromise occurred if any of the following criteria were met: pulmonary capillary wedge pressure ≥20 mm or a 25% increase; cardiac index <2.0 L/min/m
2 or a 25% decrease; ejection fraction ≤30%; pulmonary artery oxygen saturation ≤60% or a 25% decrease; presence of new S
3 gallop; fractional shortening was ≤20% or a 25% decrease; inotropic support required to manage the clinical condition.
A double-blind, randomized, comparative, parallel-group, multicenter study in primary hepatic transplant recipients was performed at centers in the United States (16), in Canada (2), in Europe (4) and in Australia (1). The total number of patients enrolled was 565. Per protocol, patients received mycophenolate mofetil 1.5 g twice daily orally or AZA 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral
® ) and corticosteroids as maintenance immunosuppressive therapy. The actual median oral dose of AZA on study was 1.5 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) initially and 1.26 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) at 12 months. The two primary endpoints were: (1) the proportion of patients who experienced, in the first 6 months post-transplantation, one or more episodes of biopsy-proven and treated rejection or death or re-transplantation, and (2) the proportion of patients who experienced graft loss (death or re-transplantation) during the first 12 months post-transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection and for the occurrence of graft loss (death or re-transplantation) for 1 year.
In combination with corticosteroids and cyclosporine, mycophenolate mofetil demonstrated a lower rate of acute rejection at 6 months and a similar rate of death or re-transplantation at 1 year compared to AZA (
Table 12
).
Table 12 De Novo Liver Transplantation Study Rejection at 6 Months/Death or Retransplantation at 1 Year
AZA
N = 287
MYCOPHENOLATE MOFETIL
N = 278
Biopsy-proven, treated rejection at 6 months (includes death or re-transplantation)
137 (47.7%)
107 (38.5%)
Death or re-transplantation at 1 year
42 (14.6%)
41 (14.7%)
Package label
MYHIBBIN Oral Suspension, 200 mg/mL - NDC 24338-018-01 - 175 mL Carton label
MYHIBBIN Oral Suspension, 200 mg/mL - NDC 24338-018-01 - 175 mL Bottle label
carton label
bottle label
1 organization
1 product
Product
Mycophenolate mofetilOrganization
Azurity Pharmaceuticals, Inc.